CML

29 registered clinical trials studyying CML — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy NCT06047886	University of Alabama at Birmingham	Phase 1
Recruiting	Study of Olverembatinib (HQP1351) in Patients With CP-CML NCT06423911	Ascentage Pharma Group Inc.	Phase 3
Recruiting	Assessment of Measurable Residual Disease in Allo-HSCT Using Digital Polymerase Chain Reaction NCT06211166	Peking University People's Hospital	—
Recruiting	Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution NCT06131801	Children's Hospital Medical Center, Cincinnati	—
Active Not Recruiting	Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients NCT05823571	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Phase 1
Completed	A Dose Calibration Study Comparing IkT-001Pro to Imatinib Mesylate 400mg NCT05623774	Inhibikase Therapeutics	Phase 1
Recruiting	A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia NCT05304377	Enliven Therapeutics	Phase 1
Unknown	FLOR3 Gene Polymorphism in Predicting Outcomes of Tyrosine Kinase Inhibitor（TKI）Stopping in Chronic Myeloid Le NCT05152537	Affiliated Hospital of Nantong University	—
Unknown	Study of Treatment Free Remission in Patients With Chronic Myeloid Leukemia in Chronic Phase NCT05926128	Fundaleu	N/A
Completed	Palatability (Taste) of Oral Formulations of Bosutinib NCT03747679	Pfizer	Phase 1
Completed	Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukem NCT03578367	Novartis Pharmaceuticals	Phase 2
Completed	Iclusig® (Ponatinib) in Clinical Practice for the Treatment of Chronic Myeloid Leukemia or Ph+ Acute Lymphobla NCT03678454	Incyte Biosciences Benelux	—
Completed	Distress, Medication Adherence and Care Needs in Patients With CML and GIST Receiving Oral Targeted Therapy NCT03880617	National Taiwan University Hospital	—
Completed	A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation NCT01744665	Novartis Pharmaceuticals	Phase 2
Unknown	Treatment Modification Based on Early Assessment of CML Patients NCT01762969	Rabin Medical Center	Phase 2
Terminated	Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations NCT01131325	Novartis Pharmaceuticals	Phase 4
Completed	An Exploratory Study of High-dose Glivec in Patients With CML-CP Using Molecular Endpoints NCT01216085	Novartis Pharmaceuticals	Phase 2
Completed	Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) NCT01019317	M.D. Anderson Cancer Center	Phase 2
Completed	A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic NCT00964873	Synta Pharmaceuticals Corp.	Phase 1
Completed	STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders NCT00858572	Synta Pharmaceuticals Corp.	Phase 1
Completed	Tasigna in Glivec-resistant or Intolerant Patients in CML NCT01206088	Novartis Pharmaceuticals	Phase 4
Completed	Umbilical Cord Blood Transplant for Hematological Malignancies NCT00891592	University of Pennsylvania	Phase 1
Unknown	Feasibility and Efficacy Study of Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) NCT00815568	Samsung Medical Center	Phase 2
Completed	Safety Study of IL-7 in Recipients of a Hemopoietic Stem Cell Transplant Peripheral Blood Stem Cell Transplant NCT00684008	Cytheris, Inc.	Phase 1
Completed	Sirolimus in Combination With MEC in High Risk Myeloid Leukemias NCT00780104	Abramson Cancer Center at Penn Medicine	Phase 1
Terminated	Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies NCT00776373	Abramson Cancer Center at Penn Medicine	Phase 1 / Phase 2
Completed	CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation NCT00333190	Dana-Farber Cancer Institute	N/A
Completed	Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic NCT00013533	National Cancer Institute (NCI)	EARLY_Phase 1
Completed	Unrelated Stem Cell Transplantation for Adults With Hematopoietic Disorders NCT00511537	University of California, San Francisco	—